| A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation BC Michel, AR D’Avino, SH Cassel, N Mashtalir, ZM McKenzie, ... Nature cell biology 20 (12), 1410-1420, 2018 | 310 | 2018 |
| Degradation of the BAF complex factor BRD9 by heterobifunctional ligands D Remillard, DL Buckley, J Paulk, GL Brien, M Sonnett, HS Seo, ... Angewandte Chemie International Edition 56 (21), 5738-5743, 2017 | 290 | 2017 |
| An activity-guided map of electrophile-cysteine interactions in primary human T cells EV Vinogradova, X Zhang, D Remillard, DC Lazar, RM Suciu, Y Wang, ... Cell 182 (4), 1009-1026. e29, 2020 | 214 | 2020 |
| Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma GL Brien, D Remillard, J Shi, ML Hemming, J Chabon, K Wynne, ... Elife 7, e41305, 2018 | 149 | 2018 |
| Targeted protein degradation by electrophilic PROTACs that stereoselectively and site-specifically engage DCAF1 Y Tao, D Remillard, EV Vinogradova, M Yokoyama, S Banchenko, ... Journal of the American Chemical Society 144 (40), 18688-18699, 2022 | 46 | 2022 |
| Assessment of bromodomain target engagement by a series of BI2536 analogues with miniaturized BET‐BRET LW Koblan, DL Buckley, CJ Ott, ME Fitzgerald, SWJ Ember, JY Zhu, S Liu, ... ChemMedChem 11 (23), 2575-2581, 2016 | 20 | 2016 |
| Dual inhibition of TAF1 and BET bromodomains from the BI-2536 kinase inhibitor scaffold D Remillard, DL Buckley, HS Seo, FM Ferguson, S Dhe-Paganon, ... ACS Medicinal Chemistry Letters 10 (10), 1443-1449, 2019 | 12 | 2019 |
| A novel β-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer H Tanton, T Sewastianik, HS Seo, D Remillard, RS Pierre, P Bala, ... Science Advances 8 (17), eabm3108, 2022 | 10 | 2022 |
| Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities Y Zhang, D Remillard, U Onubogu, B Karakyriakou, JN Asiaban, ... Nature structural & molecular biology 30 (8), 1160-1171, 2023 | 9 | 2023 |
| Chemoproteomics enabled discovery of selective probes for NuA4 factor BRD8 D Remillard, NA Savage, AT Kedves, J Paulk, X Chen, FJ Garcia, ... ACS Chemical Biology 16 (11), 2185-2192, 2021 | 4 | 2021 |
| Chemical Proteomic Discovery of Isotype‐Selective Covalent Inhibitors of the RNA Methyltransferase NSUN2 Y Tao, JG Felber, Z Zou, E Njomen, JR Remsberg, D Ogasawara, C Ye, ... Angewandte Chemie International Edition 62 (51), e202311924, 2023 | 3 | 2023 |
| Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use D BUCKLEY, J Bradner, DI REMILLARD | 2 | 2017 |
| Correction to “Targeted Protein Degradation by Electrophilic PROTACs that Stereoselectively and Site-Specifically Engage DCAF1” Y Tao, D Remillard, EV Vinogradova, M Yokoyama, S Banchenko, ... Journal of the American Chemical Society 145 (23), 12948-12948, 2023 | | 2023 |
| Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use D Buckley, J Bradner, DI Remillard US Patent 11,285,218, 2022 | | 2022 |
| A novel-catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer H Tanton, T Sewastianik, HS Seo, D Remillard, RS Pierre, P Bala, ... | | 2022 |
| Chemical Tools to Study Bromodomains in Cancer DI Remillard Harvard University, 2018 | | 2018 |
| Back Cover: Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET‐BRET (ChemMedChem 23/2016) LW Koblan, DL Buckley, CJ Ott, ME Fitzgerald, SWJ Ember, JY Zhu, S Liu, ... ChemMedChem 11 (23), 2638-2638, 2016 | | 2016 |
